ACLARA Undeterred by Caliper Tactics.Business Editors & Health/Legal Writers MOUNTAIN VIEW, Calif.--(BW HealthWire)--Jan. 18, 2000 ACLARA BioSciences, Inc. announced that Caliper caliper Instrument that consists of two adjustable legs or jaws for measuring the dimensions of material parts. Spring calipers have an adjusting screw and nut; firm-joint calipers use friction at the joint to hold the legs unmoving. Technologies (Nasdaq:CALP CALP Cognitive Academic Language Proficiency CALP Cristalleria Artistica La Piana (All the World, Crystalware) CALP Calsenilin-Like Protein CALP Centro de Astrofísica en la Palma (Canary Islands, Spain) ) has filed a complaint against it in the U.S. District Court for the Northern District of California. The complaint alleges infringement of four U.S. patents licensed to Caliper (the "Oak Ridge Oak Ridge, city (1990 pop. 27,310), Anderson and Roane counties, E Tenn., on Black Oak Ridge and the Clinch River; founded by the U.S. government 1942, inc. as an independent city 1959. patents"). The earliest of the Oak Ridge patents was issued in January 1999. ACLARA sued Caliper in April, 1999 for infringement of its U.S. Patent No. 5,750,015, which is a continuation-in-part of an application filed in February, 1990. Caliper has pleaded to the court that its action is related to this ACLARA lawsuit against Caliper. All of the Oak Ridge patents were filed in August 1994 or later. "We believe that Caliper's claims are baseless and without merit, and that we will prevail in this new action. Furthermore, we believe that this is yet another attempt by Caliper to deflect our enforcement of the `015 patent against them," explained Joseph M. Limber, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "We expect these diversionary tactics diversionary tactics npl → tácticas fpl de diversión diversionary tactics npl → tactique fsg de diversion diversionary tactics to fail in the courts, and we will not be deterred from enforcing our fundamental intellectual property in the microfluidics field." Mr. Limber continued, "In addition to our own intellectual property, ACLARA is able to benefit from the intellectual property and market position of our co-development partner, PE Biosystems. This enables us to pursue broadly key market opportunities in genomics and pharmaceutical research. We believe that our approach is being recognized as a preferred strategy for accessing these markets with microfluidics technology." ACLARA BioSciences is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. that has established state of the art technology in microfabrication and microfluidics to advance new tools for drug discovery and genomics. By performing integrated sample processing and analysis on plastic and glass microfluidic array chips, these tools enable the rapid, parallel processing parallel processing, the concurrent or simultaneous execution of two or more parts of a single computer program, at speeds far exceeding those of a conventional computer. of large numbers of samples while requiring only minute volumes of expensive or rare reagents. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion